ABSTRACT Bronchial mucosal biopsies were obtained during fibreoptic bronchoscopy in 12 patients receiving a new semisynthetic penicillin, piperacillin. The piperacillin levels estimated in bronchial mucosa exceeded those required to eradicate organisms associated with acute bronchitis, Haemophilus influenzae and Streptococcus pneumoniae, and compared favourably with those required for activity against a wide variety of anaerobic and Gram-negative organisms including Pseudomonas aeruginosa. Sputum and serum piperacillin levels were obtained from eight patients with bronchial disease receiving a five to seven day course (8 to 16 g/day). Sputum/serum level ratios were constant for the two dosages (10.7 % for 8 g/day; 14-3 % for 16 g/day) suggesting a diffusion transfer process, although the presence of pus in the sputum appeared to facilitate penetration. Seven patients achieved sputum levels exceeding those required for activity against Haemophilus influenzae and Streptococcus influenzae, and four for Pseudomonas aer-uginosa. This study provides pharmacokinetic support of the use of piperacillin in bronchopulmonary infection.
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Piperacillin sodium is a new semisynthetic penicillin which possesses a wide range of antibacterial activity against aerobic Gram-positive and Gram-negative bacteria, particularly Pseudomonas aeruginosa, and also against anaerobic organisms.1-5 Piperacillin is active against many Klebsiellapneumoniae and Gramnegative organisms resistant to carbenicillin and ticarcillin and possesses greatest activity against those organisms susceptible to all three antibiotics.6-9 Pharmacokinetic studies indicate that piperacillin has an average half-life of one hour in healthy subjects and a high renal clearance because of tubular excretion which may become saturated at high serum concentrations.'0 11 Piperacillin has been shown to provide effective therapy for serious infections caused by susceptible organisms, although the rate of emergence of resistant organisms during treatment requires investigation. 12 The purpose of this study was to evaluate the penetration of piperacillin into bronchial mucosa and sputum and to compare the piperacillin concentrations achieved with the in vitro antibacterial activity of the antibiotic.
Methods

STUDY ONE
Twelve patients who were having fibreoptic bronchoscopy for investigation of pulmonary disease were selected for this study. Informed, written con Range 5-5-6-6
11-0-13-1 9-9-20-8 7 2
Mean 2-9 5-2 3-9 SE 2-9 5-2 2-9 Range 0 -5-8 0 -10-4 10-6-7 secretion and bronchial mucosal piperacillin concentrations for the 12 patients are shown in table 3. Bronchial secretions were mucoid in all patients except in three in whom secretions were bloodstained and there were two patients in whom some of the bronchial biopsies appeared slightly bloodstained (see table 3 ). Both serum (p < 0-01) and bronchial secretion (p < 0 05) but not bronchial mucosal levels were significantly higher with the 4 g than with the 2 g dose. The pleural fluid and serum piperacillin levels in the two patients are shown in table 3 .
STUDY TWO
The mean ± SE serum and sputum piperacillin levels for the eight patients are shown in tables 4 and 5 respectively. The degree of sputum purulence is indicated in table 2. Haemophilus influtenzae was cultured from sputum before and after treatment in patient 3 (table 2) . Sputum piperacillin levels were compared with the degree of sputum purulence and with both doses there was a positive correlation (r = 0 47, p < 0 001), although when the doses were considered separately, there was a positive correlation only with the 16 g/day dose (8 g/day: r = 0-27, p > 0-10; 16 g/day: r = 0 43, p < 0 01). To assess the concentration of piperacillin in the sputum and serum over the total period of measurement, the areas under the curves (AUC) from 0 5 to 4 hours were calculated for each patient on each study day and the mean ± SE results are shown in table 6. The ratios of AUC sputum/AUC serum were calculated as an assessment of sputum penetration of piperacillin and the mean ± SE results are shown in table 6. There was a significant increase in sputum (p < 0-01) and serum AUCs (p < 0 001) but not in sputum AUC/serum AUC ratios with the 16 g/day compared with the 8 g/day dose. There was a significant positive correlation between sputum AUC/serum AUC ratio and sputum purulence (r = 0 54, p < 0 01). There were no significant changes in renal 
Discussion
Serum, bronchial mucosa, and sputum piperacfllin levels were measured in this study to assess the potential of piperacillin for the treatment of bronchopulmonary infection. Bronchial tissue antibiotic concentration will be relevant for the treatment of aspiration lung abscess which starts as a local suppurative infection in bronchi or bronchioles and spreads into the lung and in bronchopneumonia. Antibiotic concentration is likely to be higher in alveolar tissue than in bronchi because of the enormous surface area contact between alveolar walls and capillaries and in lobar pneumonia, an acinar disease primarily, serum antibiotic levels may be more relevant.
Bronchial infection may coexist with pneumonia in patients with chronic bronchitis and emphysema and the most common infecting organisms are Haemophilus influenzae and Streptococcus pneumoniae. 13 The bronchial mucosa is the site of infection in acute exacerbations of chronic bronchitis and the eradication of infection will depend upon bronchial mucosal antibiotic concentration. It is assumed that a gradient of concentration of antibiotic exists from blood through bronchial mucosa to bronchial secretions. Bronchial secretions act as a reservoir for bacterial growth which may produce reinfection if not suppressed adequately by appropriate sputum antibiotic levels.
There have been few studies which have examined antibiotic concentrations in vivo in human lung and bronchus. Surgically resected lung tissue may be used by dosing the patient before surgery. Liss and Norman,'4 using a fluorescence technique, showed a lower doxycycline concentration in alveolar tissue than in bronchiolar epithelium but this did not correlate with the assayed concentration. Gartmannl5 found that lung but not bronchial doxycycline levels were higher than in serum, whereas Kroening16 found the ratio of whole blood to lung tobramycin concentration to be 2:1. Both investigators comment concerning the need to remove blood from the specimen which must inevitably be incomplete and may result also in loss of tissue antibiotic. Kroening16 determined the haemoglobin concentration of the supernatant fluid after centrifugation of the lung tissue and applied a mathematical formula to assess lung concentration without blood admixture.
This study demonstrates a new method for obtaining bronchial mucosa for antibiotic level estimation by biopsy during fibreoptic bronchoscopy. The advantage of this procedure is that the biopsies are Piperacitlin in bronchial mucosa and sputum relatively atraumatic, although in two patients slight bloodstaining was apparent in some biopsies and this blood would have contributed to the piperacillin concentration achieved. In future studies such biopsy specimens should be discarded. The similar range of bronchial mucosal levels with the two doses suggests some saturation of the transfer process of antibiotic from blood into bronchial mucosa. Microbiological studies of piperacillin sensitivity have indicated that 100 % of Streptococcus pneumoniae and Haemophilus influenzae are susceptible at concentrations less than 0.1 and 0-25 ,ug/ml respectively,25 75 doxycycline22 levels which tend to rise as treatment progresses. Piperacillin sputum levels were above those required for Haemophilus influenzae and Streptococcus pneumoniae on the first two days in seven of the eight patients. In four patients, levels greater than 8 u.tg/ml were achieved during the course of treatment, indicating efficacy against Pseudomonas aeruginosa which may be a pathogen bronchiectasis and cystic fibrosis. Sputum penetration of piperacillin appears similar to carbenicillin which has been studied in patients with cystic fibrosis by Marks et at23 who found sputum/serum carbenicillin level ratios to be always less than 20 %.
The efficacy of an antibiotic in the treatment of infection can only be assessed by the clinical response of the patient. However, the measurement of serum, bronchial mucosa, and sputum levels of antibiotic may together provide a guide to the potential value of an antibiotic in bronchopulmonary infection. These results indicate that piperacillin may provide effective chemotherapy against a wide variety of infecting organisms in bronchopulmonary infection and that clinical studies with this antibiotic are warranted because of the increasing emergence of resistance among organisms to currently available antibiotics.
